<DOC>
	<DOC>NCT02565186</DOC>
	<brief_summary>This is a prospective, randomized, open-label study in subjects with migraine who have completed CoLucid Phase 3 study, COL MIG 301 or COL MIG-302. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.</brief_summary>
	<brief_title>An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1. Able and willing to give written informed consent and authorize HIPAA. 2. Completed COL MIG301 or COL MIG302 within the last 4 weeks. 3. Females of childbearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner). 4. Able and willing to complete an electronic diary to record details of all migraine attacks treated with study drug. 1. Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the subject unsuitable for the study. 2. Pregnant or breastfeeding women. 3. Women of childbearing potential not using or not willing to use highly effective contraception. 4. Subject is at imminent risk of suicide (positive response to question 4 or 5 on the C SSRS). 5. Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes since completing COL MIG301 or COL MIG302. 6. Participation in any clinical trial of an experimental drug or device since completing EoS/Visit 2 of COL MIG 301 or COL MIG302.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>